Trial Profile
Hepatocyte Growth Factor to Improve Functioning in Peripheral Artery Disease: The HI-PAD Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Peripheral arterial disorders
- Focus Therapeutic Use
- Acronyms HI-PAD
- 01 Nov 2023 Status changed from active, no longer recruiting to completed.
- 25 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 24 Apr 2023 Planned End Date changed from 1 Jul 2023 to 1 Aug 2023.